We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Bleeding Study: Risk and Protective Factors Associated With Bleeding in the Hemodialysis Population

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00182117
Recruitment Status : Unknown
Verified September 2005 by McMaster University.
Recruitment status was:  Recruiting
First Posted : September 16, 2005
Last Update Posted : January 24, 2006
Sponsor:
Collaborator:
Information provided by:

Study Description
Brief Summary:
This study is examining the risk and protective factors associated with bleeding in the hemodialysis population.

Condition or disease
Bleeding End Stage Renal Disease

Study Design

Study Type : Observational
Estimated Enrollment : 490 participants
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Retrospective
Official Title: Pilot Bleeding Study
Study Start Date : October 2003
Estimated Study Completion Date : April 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding
U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is undergoing hemodialysis

Exclusion Criteria:

  • This is an observational study. No exclusion criteria required.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00182117


Contacts
Contact: Christian G Rabbat, MD 905-522-1155 ext 3542 rabbatc@mcmaster.ca
Contact: Catherine M Clase, MD 905-522-1155 ext 6094 clase@mcmaster.ca

Locations
Canada, Ontario
St. Joseph's Healthcare Recruiting
Hamilton, Ontario, Canada, L8N 4A6
Contact: Christian G Rabbat, MD    905-522-1155 ext 6094    rabbatc@mcmaster.ca   
Contact: Catherine M Clase, MD    905-522-1155 ext 6094    clase@mcmaster.ca   
Sponsors and Collaborators
Hamilton Health Sciences Corporation
St. Joseph's Healthcare Hamilton
Investigators
Principal Investigator: Christian G Rabbat, MD Assistant Professor, Medicine
More Information

ClinicalTrials.gov Identifier: NCT00182117     History of Changes
Other Study ID Numbers: Division of Nephrology Funds
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: January 24, 2006
Last Verified: September 2005

Keywords provided by McMaster University:
bleeding
end stage renal disease
antiplatelet therapy
anticoagulant therapy
hemodialysis

Additional relevant MeSH terms:
Hemorrhage
Kidney Diseases
Kidney Failure, Chronic
Pathologic Processes
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency